OBJECTIVE: To assess the impact of empiric antifungal therapy for invasive candidiasis on subsequent outcomes in premature infants. STUDY DESIGN: This was a cohort study of infants with a birth weight ≤ 1000 g receiving care at Neonatal Research Network sites. All infants had at least one positive culture for Candida. Empiric antifungal therapy was defined as receipt of a systemic antifungal on the day of or the day before the first positive culture for Candida was drawn. We created Cox proportional hazards and logistic regression models stratified on propensity score quartiles to determine the effect of empiric antifungal therapy on survival, time to clearance of infection, retinopathy of prematurity, bronchopulmonary dysplasia, end-organ damage, and neurodevelopmental impairment (NDI). RESULTS: A total of 136 infants developed invasive candidiasis. The incidence of death or NDI was lower in infants who received empiric antifungal therapy (19 of 38; 50%) compared with those who had not (55 of 86; 64%; OR, 0.27; 95% CI, 0.08-0.86). There was no significant difference between the groups for any single outcome or other combined outcomes. CONCLUSION: Empiric antifungal therapy was associated with increased survival without NDI. A prospective randomized trial of this strategy is warranted.
OBJECTIVE: To assess the impact of empiric antifungal therapy for invasive candidiasis on subsequent outcomes in premature infants. STUDY DESIGN: This was a cohort study of infants with a birth weight ≤ 1000 g receiving care at Neonatal Research Network sites. All infants had at least one positive culture for Candida. Empiric antifungal therapy was defined as receipt of a systemic antifungal on the day of or the day before the first positive culture for Candida was drawn. We created Cox proportional hazards and logistic regression models stratified on propensity score quartiles to determine the effect of empiric antifungal therapy on survival, time to clearance of infection, retinopathy of prematurity, bronchopulmonary dysplasia, end-organ damage, and neurodevelopmental impairment (NDI). RESULTS: A total of 136 infants developed invasive candidiasis. The incidence of death or NDI was lower in infants who received empiric antifungal therapy (19 of 38; 50%) compared with those who had not (55 of 86; 64%; OR, 0.27; 95% CI, 0.08-0.86). There was no significant difference between the groups for any single outcome or other combined outcomes. CONCLUSION: Empiric antifungal therapy was associated with increased survival without NDI. A prospective randomized trial of this strategy is warranted.
Authors: Daniel K Benjamin; Barbara J Stoll; Marie G Gantz; Michele C Walsh; Pablo J Sánchez; Abhik Das; Seetha Shankaran; Rosemary D Higgins; Kathy J Auten; Nancy A Miller; Thomas J Walsh; Abbot R Laptook; Waldemar A Carlo; Kathleen A Kennedy; Neil N Finer; Shahnaz Duara; Kurt Schibler; Rachel L Chapman; Krisa P Van Meurs; Ivan D Frantz; Dale L Phelps; Brenda B Poindexter; Edward F Bell; T Michael O'Shea; Kristi L Watterberg; Ronald N Goldberg Journal: Pediatrics Date: 2010-09-27 Impact factor: 7.124
Authors: X Schiel; H Link; G Maschmeyer; B Glass; O A Cornely; D Buchheidt; M Wilhelm; G Silling; M Helmerking; W Hiddemann; H Ostermann; M Hentrich Journal: Infection Date: 2006-06 Impact factor: 3.553
Authors: Peter G Pappas; Carol A Kauffman; David Andes; Daniel K Benjamin; Thierry F Calandra; John E Edwards; Scott G Filler; John F Fisher; Bart-Jan Kullberg; Luis Ostrosky-Zeichner; Annette C Reboli; John H Rex; Thomas J Walsh; Jack D Sobel Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Jan Hau Lee; Christoph P Hornik; Daniel K Benjamin; Amy H Herring; Reese H Clark; Michael Cohen-Wolkowiez; P Brian Smith Journal: Pediatr Infect Dis J Date: 2013-03 Impact factor: 2.129
Authors: Jennifer Le; Tu T Tran; Ivilynn Bui; Mike K Wang; Andrew Vo; Felice C Adler-Shohet Journal: Antimicrob Agents Chemother Date: 2013-03-18 Impact factor: 5.191
Authors: Michelle Barton; Karel O'Brien; Joan L Robinson; Dele H Davies; Kim Simpson; Elizabeth Asztalos; Joanne M Langley; Nicole Le Saux; Reg Sauve; Anne Synnes; Ben Tan; Louis de Repentigny; Earl Rubin; Chuck Hui; Lajos Kovacs; Susan E Richardson Journal: BMC Infect Dis Date: 2014-06-12 Impact factor: 3.090
Authors: Jessica E Ericson; Joshua Thaden; Heather R Cross; Reese H Clark; Vance G Fowler; Daniel K Benjamin; Michael Cohen-Wolkowiez; Christoph P Hornik; P Brian Smith Journal: Pediatr Infect Dis J Date: 2015-04 Impact factor: 3.806
Authors: Jadwiga Wójkowska-Mach; Ewa Gulczyńska; Marek Nowiczewski; Maria Borszewska-Kornacka; Joanna Domańska; T Allen Merritt; Ewa Helwich; Agnieszka Kordek; Dorota Pawlik; Janusz Gadzinowski; Jerzy Szczapa; Paweł Adamski; Małgorzata Sulik; Jerzy Klamka; Monika Brzychczy-Włoch; Piotr B Heczko Journal: BMC Infect Dis Date: 2014-06-18 Impact factor: 3.090
Authors: José Endrigo Tinoco-Araujo; Diana Ferreira Gadelha Araújo; Patrícia Gomes Barbosa; Paulo Sérgio da Silva Santos; Ana Myriam Costa de Medeiros Journal: Einstein (Sao Paulo) Date: 2013 Jan-Mar